Low serum omentin levels in the elderly population with Type 2 diabetes and polyneuropathy

2015 ◽  
Vol 32 (11) ◽  
pp. 1479-1483 ◽  
Author(s):  
C. Herder ◽  
B. W. C. Bongaerts ◽  
D. M. Ouwens ◽  
W. Rathmann ◽  
M. Heier ◽  
...  
Nutrients ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 183
Author(s):  
Anna Izzo ◽  
Elena Massimino ◽  
Gabriele Riccardi ◽  
Giuseppe Della Pepa

Type 2 diabetes mellitus (T2DM) represents a major health burden for the elderly population, affecting approximately 25% of people over the age of 65 years. This percentage is expected to increase dramatically in the next decades in relation to the increased longevity of the population observed in recent years. Beyond microvascular and macrovascular complications, sarcopenia has been described as a new diabetes complication in the elderly population. Increasing attention has been paid by researchers and clinicians to this age-related condition—characterized by loss of skeletal muscle mass together with the loss of muscle power and function—in individuals with T2DM; this is due to the heavy impact that sarcopenia may have on physical and psychosocial health of diabetic patients, thus affecting their quality of life. The aim of this narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM, and (2) its association with relevant features of patients with T2DM such as age, gender, body mass index, disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs. From a clinical point of view, it is necessary to improve the ability of physicians and dietitians to recognize early sarcopenia and its risk factors in patients with T2DM in order to make appropriate therapeutic approaches able to prevent and treat this condition.


Author(s):  
Beata Dziedzic ◽  
Zofia Sienkiewicz ◽  
Anna Leńczuk-Gruba ◽  
Ewa Kobos ◽  
Wiesław Fidecki ◽  
...  

Introduction: A sharp rise in the population of elderly people, who are more prone to somatic and mental diseases, combined with the high prevalence of type 2 diabetes mellitus and diabetes-associated complications in this age group, have an impact on the prevalence of depressive symptoms. Aim of the work: The work of the study was the evaluation of the prevalence of depressive symptoms in the elderly population diagnosed with type 2 diabetes mellitus. Materials and methods: The pilot study was conducted in 2019 among 200 people diagnosed with type 2 diabetes mellitus, aged 65 years and above, receiving treatment in a specialist diabetes outpatient clinic. The study was based on a questionnaire aimed at collecting basic sociodemographic and clinical data and the complete geriatric depression scale (GDS, by Yesavage) consisting of 30 questions. Results: The study involved 200 patients receiving treatment in a diabetes outpatient clinic. The mean age of the study subjects was 71.4 ± 5.0 years. The vast majority of the subjects (122; 61%) were women, with men accounting for 39% of the study population (78 subjects). A statistically significant difference in the GDS (p < 0.01) was shown for marital status, body mass index (BMI), duration of diabetes, and the number of comorbidities. Patients with results indicative of symptoms of mild and severe depression were found to have higher BMI, longer disease duration, and a greater number of comorbidities. There were no statistically significant differences in the level of HbA1c. Conclusions: In order to verify the presence of depressive symptoms in the group of geriatric patients with diabetes mellitus, an appropriate screening programme must be introduced to identify those at risk and refer them to specialists, so that treatment can be promptly initiated. Screening tests conducted by nurses might help with patient identification.


2006 ◽  
Vol 14 (2) ◽  
pp. 75-83 ◽  
Author(s):  
Gary Erwin ◽  
Shrividya Iyer ◽  
Rukmini Rajagopalan ◽  
James Astuto ◽  
Patricia Wilson ◽  
...  

2000 ◽  
Vol 13 (4) ◽  
pp. 263-276 ◽  
Author(s):  
Suzanne Campbell

Type 2 diabetes is prevalent in the elderly population. In the past five years, there has been an increased number of drugs with unique mechanisms of action which have become available for the treatment of type 2 diabetes. Recent studies have shown that attaining optimal glycemic control in patients with type 2 diabetes will prevent or delay the complications associated with this disease. This article will review the management of type 2 diabetes.


2016 ◽  
Vol 11 (1) ◽  
pp. 93-94 ◽  
Author(s):  
Win Myat Maw ◽  
Mi Mi Saw ◽  
Theingi Kyaw ◽  
Khin Ohnmar Kyaing ◽  
Zaw Min Latt ◽  
...  

2011 ◽  
Vol 68 (6) ◽  
pp. 500-509 ◽  
Author(s):  
Michelle A. Fravel ◽  
Deanna L. McDanel ◽  
Mary B. Ross ◽  
Kevin G. Moores ◽  
Mary J. Starry

Sign in / Sign up

Export Citation Format

Share Document